Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival
International Journal of Cancer · 15.05.2026 · 158 (10) · 2697-2708
DOI: 10.1002/ijc.70312 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Cancer, online erschienen am 24.12.2025. Verfasst von Michael Masetti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III (Hematology and Oncology), Klinikum Rechts der Isar, Technische Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Immune‐checkpoint‐inhibition (ICI) represents the mainstay for treatment of advanced gastroesophageal cancer (GEC) in most cases. Sex differences in innate and adaptive immune responses are known to reflect distinct anti‐tumor efficacy of ICI in female and male patients. However, most randomized controlled trials (RCTs) on ICI in GEC were conducted without taking sex differences into account. To address this uncertainty, we conducted a meta‐analysis across first‐line (1L) RCTs in advanced GEC. Systematic research was performed up to March 31, 2025. The primary endpoint was the pooled hazard ratio (HR) for overall survival (OS) in male and female patients, comparing ICI‐based therapy versus control. The secondary objective was to assess the interaction between sex and treatment effect. A total of 15 RCTs were included (7 trials on ESCC and 8 trials on GEA). In male ESCC patients, the pooled HR for OS favored ICI with statistical significance (HR = 0.70, 95% CI = 0.65–0.76, P < .00001). In women, HR was 0.81 (95% CI = 0.61–1.07, P = .14). In GEA, ICI‐ based therapy showed significant survival benefits in both men (HR = 0.78, 95% CI = 0.73–0.83, P < .00001) and women (HR = 0.82, 95% CI = 0.75–0.90, P < .0001). The test for interaction between sexes and treatment effect indicated no significant difference in ICI efficacy between sexes in ESCC (Chi 2 = 1.02, P = .31) and GEA (Chi 2 = 0.78, P = .38). In advanced ESCC, only men showed a statistically significant OS benefit from ICI‐based treatment, but the difference between sexes was not statistically significant. In GEA, both sexes had similar survival benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III (Hematology and Oncology), Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
- Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest, Treviglio, Italy.
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ORCID-Profile: Michael Masetti, Filippo Pietrantonio
Förderung
- Fondazione AIRC associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Masetti, M., Petrelli, F., Pietrantonio, F., Lorenzen, S., & Leone, A. G. (2026). Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival. International Journal of Cancer, 158(10), 2697-2708. https://doi.org/10.1002/ijc.70312
Vancouver
Masetti M, Petrelli F, Pietrantonio F, Lorenzen S, Leone AG. Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival. International Journal of Cancer. 2026;158(10):2697-2708. doi:10.1002/ijc.70312
BibTeX
@article{Masetti2026,
author = {Masetti, Michael and Petrelli, Fausto and Pietrantonio, Filippo and Lorenzen, Sylvie and Leone, Alberto Giovanni},
title = {Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival},
journal = {International Journal of Cancer},
year = {2026},
volume = {158},
number = {10},
pages = {2697--2708},
doi = {10.1002/ijc.70312}
}
EUVIMED